|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SHTN1 |
Gene summary for SHTN1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SHTN1 | Gene ID | 57698 |
| Gene name | shootin 1 | |
| Gene Alias | KIAA1598 | |
| Cytomap | 10q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | A0MZ66 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57698 | SHTN1 | CA_HPV_2 | Human | Cervix | CC | 4.52e-02 | 2.18e-01 | 0.0391 |
| 57698 | SHTN1 | HSIL_HPV_2 | Human | Cervix | HSIL_HPV | 2.97e-04 | 2.55e-01 | 0.0208 |
| 57698 | SHTN1 | CCI_2 | Human | Cervix | CC | 2.73e-02 | 5.47e-01 | 0.5249 |
| 57698 | SHTN1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 9.11e-14 | -5.58e-01 | 0.0155 |
| 57698 | SHTN1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.19e-06 | -5.18e-01 | -0.1808 |
| 57698 | SHTN1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.02e-02 | -4.74e-01 | -0.0811 |
| 57698 | SHTN1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.10e-03 | -5.03e-01 | -0.1207 |
| 57698 | SHTN1 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.86e-03 | -5.37e-01 | -0.1526 |
| 57698 | SHTN1 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.71e-17 | -5.01e-01 | -0.1464 |
| 57698 | SHTN1 | HTA11_866_2000001011 | Human | Colorectum | AD | 3.36e-20 | -5.48e-01 | -0.1001 |
| 57698 | SHTN1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.42e-07 | -4.89e-01 | -0.059 |
| 57698 | SHTN1 | HTA11_546_2000001011 | Human | Colorectum | AD | 3.25e-04 | -5.85e-01 | -0.0842 |
| 57698 | SHTN1 | HTA11_9341_2000001011 | Human | Colorectum | SER | 4.26e-02 | -6.71e-01 | -0.00410000000000005 |
| 57698 | SHTN1 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.53e-13 | -5.71e-01 | 0.096 |
| 57698 | SHTN1 | HTA11_9408_2000001011 | Human | Colorectum | AD | 1.32e-02 | -6.71e-01 | 0.0451 |
| 57698 | SHTN1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.40e-04 | -6.47e-01 | 0.0528 |
| 57698 | SHTN1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 7.85e-08 | -5.77e-01 | 0.0338 |
| 57698 | SHTN1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.57e-21 | -5.57e-01 | 0.0674 |
| 57698 | SHTN1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 4.64e-02 | -4.53e-01 | 0.0588 |
| 57698 | SHTN1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.86e-10 | -3.69e-01 | 0.294 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
| GO:00071639 | Cervix | CC | establishment or maintenance of cell polarity | 63/2311 | 218/18723 | 4.25e-11 | 8.76e-09 | 63 |
| GO:00072656 | Cervix | CC | Ras protein signal transduction | 79/2311 | 337/18723 | 9.49e-09 | 7.77e-07 | 79 |
| GO:00300108 | Cervix | CC | establishment of cell polarity | 42/2311 | 143/18723 | 4.30e-08 | 2.62e-06 | 42 |
| GO:006157210 | Cervix | CC | actin filament bundle organization | 44/2311 | 161/18723 | 2.08e-07 | 9.34e-06 | 44 |
| GO:00109757 | Cervix | CC | regulation of neuron projection development | 88/2311 | 445/18723 | 4.26e-06 | 1.09e-04 | 88 |
| GO:00107206 | Cervix | CC | positive regulation of cell development | 64/2311 | 298/18723 | 5.69e-06 | 1.41e-04 | 64 |
| GO:00313467 | Cervix | CC | positive regulation of cell projection organization | 72/2311 | 353/18723 | 1.04e-05 | 2.32e-04 | 72 |
| GO:00160498 | Cervix | CC | cell growth | 92/2311 | 482/18723 | 1.16e-05 | 2.49e-04 | 92 |
| GO:00325359 | Cervix | CC | regulation of cellular component size | 76/2311 | 383/18723 | 1.66e-05 | 3.21e-04 | 76 |
| GO:00615647 | Cervix | CC | axon development | 89/2311 | 467/18723 | 1.71e-05 | 3.27e-04 | 89 |
| GO:00072666 | Cervix | CC | Rho protein signal transduction | 35/2311 | 137/18723 | 1.77e-05 | 3.33e-04 | 35 |
| GO:00074097 | Cervix | CC | axonogenesis | 78/2311 | 418/18723 | 1.14e-04 | 1.43e-03 | 78 |
| GO:00459277 | Cervix | CC | positive regulation of growth | 53/2311 | 259/18723 | 1.33e-04 | 1.64e-03 | 53 |
| GO:00015588 | Cervix | CC | regulation of cell growth | 77/2311 | 414/18723 | 1.40e-04 | 1.70e-03 | 77 |
| GO:00303077 | Cervix | CC | positive regulation of cell growth | 36/2311 | 166/18723 | 4.84e-04 | 4.75e-03 | 36 |
| GO:00507705 | Cervix | CC | regulation of axonogenesis | 34/2311 | 154/18723 | 4.87e-04 | 4.76e-03 | 34 |
| GO:00300487 | Cervix | CC | actin filament-based movement | 29/2311 | 127/18723 | 6.91e-04 | 6.33e-03 | 29 |
| GO:20001147 | Cervix | CC | regulation of establishment of cell polarity | 9/2311 | 22/18723 | 7.19e-04 | 6.49e-03 | 9 |
| GO:00486386 | Cervix | CC | regulation of developmental growth | 61/2311 | 330/18723 | 7.69e-04 | 6.85e-03 | 61 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SHTN1 | SNV | Missense_Mutation | c.1631C>T | p.Pro544Leu | p.P544L | A0MZ66 | protein_coding | deleterious(0) | benign(0.001) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SHTN1 | SNV | Missense_Mutation | novel | c.975G>C | p.Gln325His | p.Q325H | A0MZ66 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SHTN1 | insertion | Nonsense_Mutation | novel | c.1034_1035insTTCCATGCTATTCTCATGATAGTGAATCTCATGAGATCTGATG | p.Asn346SerfsTer6 | p.N346Sfs*6 | A0MZ66 | protein_coding | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
| SHTN1 | insertion | Nonsense_Mutation | novel | c.1031_1032insTTCTCTCTTCCCTGCTGCCATGTAAGATGTGACTTGCTTCTCCTT | p.Arg344_Val345insSerLeuPheProAlaAlaMetTerAspValThrCysPheSerLeu | p.R344_V345insSLFPAAM*DVTCFSL | A0MZ66 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| SHTN1 | SNV | Missense_Mutation | novel | c.117C>A | p.Asp39Glu | p.D39E | A0MZ66 | protein_coding | tolerated(0.29) | possibly_damaging(0.496) | TCGA-EK-A2PL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| SHTN1 | insertion | In_Frame_Ins | novel | c.465_466insTCTGAAATT | p.Gln155_Glu156insSerGluIle | p.Q155_E156insSEI | A0MZ66 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | ||
| SHTN1 | SNV | Missense_Mutation | novel | c.443N>A | p.Arg148Gln | p.R148Q | A0MZ66 | protein_coding | tolerated(0.6) | benign(0.006) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| SHTN1 | SNV | Missense_Mutation | c.1654N>C | p.Ser552Arg | p.S552R | A0MZ66 | protein_coding | tolerated(0.11) | benign(0.003) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SHTN1 | SNV | Missense_Mutation | c.716N>C | p.Phe239Ser | p.F239S | A0MZ66 | protein_coding | deleterious(0.01) | benign(0.005) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| SHTN1 | SNV | Missense_Mutation | novel | c.452N>G | p.Ile151Ser | p.I151S | A0MZ66 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |